In the News


New drugs did not change overall glycemic control in U.S. patients with type 2 diabetes, study finds

The proportion of type 2 diabetes patients with HbA1c levels of 9% or greater or HbA1c between 8% and 9% increased from 2006 to 2013, while the proportion with an HbA1c less than 6% decreased.

3 biomarkers may refine standard cardiovascular risk algorithms for diabetes

Elevations in high-sensitivity troponin T or N-terminal pro-B-type natriuretic peptide were significantly associated with risk of cardiovascular death, myocardial infarction, and hospitalization for heart failure, while C-reactive protein was a less significant predictor.

Weekly GLP-1 analogue associated with reduced MI, stroke risk, industry study finds

The trial of semaglutide included 3,297 patients with type 2 diabetes, 83% of whom had established cardiovascular disease, chronic kidney disease, or both.

MKSAP quiz: Management of new type 1 diabetes

This month's quiz asks readers to manage recent hypoglycemia in a 21-year-old woman diagnosed 3 months ago with type 1 diabetes after presenting to the emergency department with diabetic ketoacidosis.

Intensive glucose-lowering in type 2 diabetes was linked to hypoglycemia in high-complexity patients

More than 20% of patients with type 2 diabetes received treatment more intensive than that recommended by HbA1c-based guidelines, a study of Medicare patients found.

Beyond the Guidelines: Should we screen for type 2 diabetes?

Whether to screen a patient for type 2 diabetes is the focus of a Beyond the Guidelines feature in the Oct. 4 Annals of Internal Medicine.

Ischemic heart disease linked to worse prognosis in heart failure patients with type 2 diabetes

Mortality risk was highest in patients who had both type 2 diabetes and ischemic heart disease and had not had previous revascularization.

Spotlight on new technologies for type 1 diabetes

Two recent studies and FDA approval of the first “artificial pancreas” highlight new technological advances in type 1 diabetes care.

Physician editor: David V. O'Dell, MD, FACP